Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T. Hall PE, et al. Among authors: ackerman c. Eur Urol Focus. 2020 Sep 15;6(5):999-1005. doi: 10.1016/j.euf.2019.01.010. Epub 2019 Feb 6. Eur Urol Focus. 2020. PMID: 30738795 Free article. Clinical Trial.
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).
Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bhal A, Fife K, Webb A, Crabb S, Geldart T, Hill R, Dunlop J, Hall PE, McLaren D, Ackerman C, Beltran L, Nathan P. Powles T, et al. Among authors: ackerman c. Ann Oncol. 2016 May;27(5):880-6. doi: 10.1093/annonc/mdw014. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802156 Free article. Clinical Trial.
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
Powles T, Sarwar N, Stockdale A, Sarker SJ, Boleti E, Protheroe A, Jones R, Chowdhury S, Peters J, Oades G, O'Brien T, Sullivan M, Aitchison M, Beltran L, Worth D, Smith K, Michel C, Trevisan G, Harvey-Jones E, Wimalasingham A, Sahdev A, Ackerman C, Crabb S. Powles T, et al. Among authors: ackerman c. JAMA Oncol. 2016 Oct 1;2(10):1303-1309. doi: 10.1001/jamaoncol.2016.1197. JAMA Oncol. 2016. PMID: 27254750 Clinical Trial.
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S. Powles T, et al. Among authors: ackerman c. J Clin Oncol. 2017 Jan;35(1):48-55. doi: 10.1200/JCO.2015.66.3468. Epub 2016 Oct 28. J Clin Oncol. 2017. PMID: 28034079 Free article. Clinical Trial.
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
Powles T, Gómez de Liaño A, Ackerman C. Powles T, et al. Among authors: ackerman c. Eur Urol. 2017 Nov;72(5):e137-e138. doi: 10.1016/j.eururo.2017.05.025. Epub 2017 Jun 9. Eur Urol. 2017. PMID: 28606457 No abstract available.
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly JD. Tan WS, et al. Among authors: ackerman c. Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20. Eur Urol. 2023. PMID: 35999119 Free article. Clinical Trial.
161 results